Cowens JW - Search Results

1

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.

Weng DE, Masci PA, Radka SF, Jackson TE, Weiss PA, Ganapathi R, Elson PJ, Capra WB, Parker VP, Lockridge JA, Cowens JW, Usman N, Borden EC. Weng DE, et al. Among authors: cowens jw. Mol Cancer Ther. 2005 Jun;4(6):948-55. doi: 10.1158/1535-7163.MCT-04-0210. Mol Cancer Ther. 2005. PMID: 15956252 Clinical Trial.

2

Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

Cowens JW, Creaven PJ, Greco WR, Brenner DE, Tung Y, Ostro M, Pilkiewicz F, Ginsberg R, Petrelli N. Cowens JW, et al. Cancer Res. 1993 Jun 15;53(12):2796-802. Cancer Res. 1993. PMID: 8504422 Clinical Trial.

3

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days.

Creaven PJ, Brenner DE, Cowens JW, Huben RP, Wolf RM, Takita H, Arbuck SG, Razack MS, Proefrock AD. Creaven PJ, et al. Among authors: cowens jw. Cancer Chemother Pharmacol. 1989;23(3):186-91. doi: 10.1007/BF00267953. Cancer Chemother Pharmacol. 1989. PMID: 2924376

4

Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer.

Creaven PJ, Cowens JW, Brenner DE, Dadey BM, Han T, Huben R, Karakousis C, Frost H, LeSher D, Hanagan J, et al. Creaven PJ, et al. Among authors: cowens jw. J Biol Response Mod. 1990 Oct;9(5):492-8. J Biol Response Mod. 1990. PMID: 2254761 Clinical Trial.

5

Studies on the human metabolism of iproplatin.

Pendyala L, Krishnan BS, Walsh JR, Arakali AV, Cowens JW, Creaven PJ. Pendyala L, et al. Among authors: cowens jw. Cancer Chemother Pharmacol. 1989;25(1):10-4. doi: 10.1007/BF00694331. Cancer Chemother Pharmacol. 1989. PMID: 2590996

6

Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks.

Creaven PJ, Cowens JW, Huben R, Petrelli N, Karakousis C, Traynor D. Creaven PJ, et al. Among authors: cowens jw. Cancer Chemother Pharmacol. 1989;23(4):266-7. doi: 10.1007/BF00451655. Cancer Chemother Pharmacol. 1989. PMID: 2924383

7

DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II).

Pendyala L, Arakali AV, Sansone P, Cowens JW, Creaven PJ. Pendyala L, et al. Among authors: cowens jw. Cancer Chemother Pharmacol. 1990;27(3):248-50. doi: 10.1007/BF00685722. Cancer Chemother Pharmacol. 1990. PMID: 2265462

8

Uptake and metabolism of iproplatin in murine L1210 cells.

Pendyala L, Walsh JR, Huq MM, Arakali AV, Cowens JW, Creaven PJ. Pendyala L, et al. Among authors: cowens jw. Cancer Chemother Pharmacol. 1989;25(1):15-8. doi: 10.1007/BF00694332. Cancer Chemother Pharmacol. 1989. PMID: 2590997

9

Phase I clinical trial of ethyl 6-deoxy-3,5-di-O-methyl 6-(3 methyl-3-nitrosoureido)-alpha-D-glucofuranoside (CGP 6809).

Creaven PJ, Madajewicz S, Cowens JW, Plager JE, Pendyala L, Mittelman A, Petrelli N, Karakousis C, Huben R, Takita H, et al. Creaven PJ, et al. Among authors: cowens jw. Cancer Chemother Pharmacol. 1987;20(1):37-40. doi: 10.1007/BF00252957. Cancer Chemother Pharmacol. 1987. PMID: 3304687 Clinical Trial.

10

Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans.

Pendyala L, Cowens JW, Chheda GB, Dutta SP, Creaven PJ. Pendyala L, et al. Among authors: cowens jw. Cancer Res. 1988 Jun 15;48(12):3533-6. Cancer Res. 1988. PMID: 3370646

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page